JP2021514999A5 - - Google Patents

Info

Publication number
JP2021514999A5
JP2021514999A5 JP2020545293A JP2020545293A JP2021514999A5 JP 2021514999 A5 JP2021514999 A5 JP 2021514999A5 JP 2020545293 A JP2020545293 A JP 2020545293A JP 2020545293 A JP2020545293 A JP 2020545293A JP 2021514999 A5 JP2021514999 A5 JP 2021514999A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
alkoxy
halo
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020545293A
Other languages
English (en)
Japanese (ja)
Other versions
JP7305664B2 (ja
JP2021514999A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020395 external-priority patent/WO2019169326A1/en
Publication of JP2021514999A publication Critical patent/JP2021514999A/ja
Publication of JP2021514999A5 publication Critical patent/JP2021514999A5/ja
Application granted granted Critical
Publication of JP7305664B2 publication Critical patent/JP7305664B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020545293A 2018-03-01 2019-03-01 タンパク質アルギニンメチルトランスフェラーゼの阻害剤としてのエタンジアミン-複素環誘導体 Active JP7305664B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637147P 2018-03-01 2018-03-01
US62/637,147 2018-03-01
PCT/US2019/020395 WO2019169326A1 (en) 2018-03-01 2019-03-01 Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

Publications (3)

Publication Number Publication Date
JP2021514999A JP2021514999A (ja) 2021-06-17
JP2021514999A5 true JP2021514999A5 (cg-RX-API-DMAC7.html) 2022-02-17
JP7305664B2 JP7305664B2 (ja) 2023-07-10

Family

ID=67767960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020545293A Active JP7305664B2 (ja) 2018-03-01 2019-03-01 タンパク質アルギニンメチルトランスフェラーゼの阻害剤としてのエタンジアミン-複素環誘導体

Country Status (8)

Country Link
US (2) US11028083B2 (cg-RX-API-DMAC7.html)
EP (1) EP3758698A4 (cg-RX-API-DMAC7.html)
JP (1) JP7305664B2 (cg-RX-API-DMAC7.html)
CN (1) CN111867584A (cg-RX-API-DMAC7.html)
AU (1) AU2019226585A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017541A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092579A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019169326A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017541A2 (pt) 2018-03-01 2020-12-22 Board Of Regents, The University Of Texas System Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt
WO2022192527A1 (en) * 2021-03-12 2022-09-15 Board Of Regents, The University Of Texas System Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
JP2004149429A (ja) * 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
EP2221053A1 (de) * 2009-02-20 2010-08-25 Albert-Ludwigs-Universität Freiburg Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen
US9593109B2 (en) * 2011-08-26 2017-03-14 Cymabay Therapeutics, Inc. Bicyclic agonists of GPR131 and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9133189B2 (en) * 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
CA2903394C (en) * 2013-03-14 2021-08-31 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム,インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
EP3363434A1 (en) * 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
EP2970181B1 (en) * 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) * 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) * 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9394258B2 (en) * 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US20170283400A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044576A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
US20170280720A1 (en) * 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2016044626A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2017136699A1 (en) 2016-02-05 2017-08-10 Epizyme, Inc Arginine methyltransferase inhibitors and uses thereof
KR102148587B1 (ko) 2016-02-23 2020-08-26 화이자 인코포레이티드 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물
BR112020017541A2 (pt) 2018-03-01 2020-12-22 Board Of Regents, The University Of Texas System Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt

Similar Documents

Publication Publication Date Title
JP2021519308A5 (cg-RX-API-DMAC7.html)
US12077554B2 (en) CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US9717730B2 (en) Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
JP2015534579A5 (cg-RX-API-DMAC7.html)
JP2019510832A5 (cg-RX-API-DMAC7.html)
JP2013507415A5 (cg-RX-API-DMAC7.html)
JP2024511996A5 (cg-RX-API-DMAC7.html)
JP2020511467A5 (cg-RX-API-DMAC7.html)
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
RU2014151565A (ru) Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида
JP2016506916A5 (cg-RX-API-DMAC7.html)
JP2013523784A5 (cg-RX-API-DMAC7.html)
JP2022540421A5 (cg-RX-API-DMAC7.html)
JP2022527398A (ja) 2-(2,6-ジオキソピペリジン-3-イル)-4-((2-フルオロ-4-((3-モルホリノアゼチジン-1-イル)メチル)ベンジル)アミノ)イソインドリン-1,3-ジオンを使用する非ホジキンリンパ腫の処置方法
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
JP2019516684A5 (cg-RX-API-DMAC7.html)
JP2008540554A5 (cg-RX-API-DMAC7.html)
JP2019524714A5 (cg-RX-API-DMAC7.html)
RU2014108885A (ru) Ингибирование транзиторного рецепторного потенциала ионного канала trpa1
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物
EP3423112A1 (en) Hsp90 inhibitor drug conjugates
JP2009531441A5 (cg-RX-API-DMAC7.html)
JP2015522551A5 (cg-RX-API-DMAC7.html)
JP2017525740A5 (cg-RX-API-DMAC7.html)
CN111818925A (zh) Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途